April 12, 2018
IIVS, in collaboration with Philip Morris International, recently presented data highlighting the predictive capability of in vitro assays in determining human response to non-burn tobacco products. Moreover, a ring trial of 6 independent laboratories has generated evidence that key events involved in human disease caused by nicotine-based products can be replicated using non-animal models. These results may increase interest in the use of alternative testing strategies for research and development and, eventually, regulatory acceptance. Read article.